Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultralife (ULBI) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ultralife (ULBI) over the last 15 years, with Q3 2025 value amounting to -$651000.0.

  • Ultralife's Cash from Financing Activities rose 8403.24% to -$651000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year increase of 35861.3%. This contributed to the annual value of $29.9 million for FY2024, which is 44389.8% up from last year.
  • Latest data reveals that Ultralife reported Cash from Financing Activities of -$651000.0 as of Q3 2025, which was up 8403.24% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Ultralife's Cash from Financing Activities registered a high of $45.7 million during Q4 2024, and its lowest value of -$11.9 million during Q2 2024.
  • For the 4-year period, Ultralife's Cash from Financing Activities averaged around $2.6 million, with its median value being -$360500.0 (2021).
  • The largest annual percentage gain for Ultralife's Cash from Financing Activities in the last 5 years was 1527607.97% (2024), contrasted with its biggest fall of 86363.64% (2024).
  • Quarter analysis of 4 years shows Ultralife's Cash from Financing Activities stood at -$420000.0 in 2021, then increased by 28.33% to -$301000.0 in 2023, then surged by 15276.08% to $45.7 million in 2024, then crashed by 101.43% to -$651000.0 in 2025.
  • Its Cash from Financing Activities stands at -$651000.0 for Q3 2025, versus -$2.7 million for Q2 2025 and -$687000.0 for Q1 2025.